Abstract
The effects of intramuscular injection and subcutaneous infusion of desferrioxamine (D.F.) on urinary iron excretion were compared in eleven patients with thalassæmia major and one with congenital sideroblastic anæmia who were being maintained on regular blood-transfusions. Total (48-hour) urinary iron excretion ranged from 3·3 to 40·3 mg (mean 16·3 mg) in nine patients who received 750 mg D.F. intramuscularly before transfusion and from 3·9 to 32·3 mg (mean 11·9 mg) in ten patients who received D.F. by the same route after transfusion. In all 9 patients studied before transfusion, continuous subcutaneous infusion of 750 mg D.F. over 24 hours increased iron excretion by 61·5 to 135·8% (mean 101±25·4 S.D.%) compared with intramuscular injection of a similar dose. In the 10 patients studied after transfusion, the iron excretion produced by continuous subcutaneous infusion was from 18·9 to 213% (mean 128±74·3%) more than that produced by a single intramuscular injection of D.F. When the subcutaneous dose over 24 hours was increased to 1500 mg in six patients, 48-hour iron excretion ranged from 29·2 to 81·2 mg (mean 52·4 mg) and was increased by 80·2—794% (mean 429%) compared with the excretion when 750 mg was given by intramuscular injection. It is concluded that continuous subcutaneous infusion of D.F. produces more iron excretion in patients with iron overload than intramuscular injection. Providing a suitable portable pump can be carried by the patients, continuous subcutaneous infusion of desferrioxamine may prove a valuable means of preventing or treating iron overload in anæmic patients maintained on regular transfusions.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call